# Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses

> **NCT06587503** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University of Birmingham** · enrollment: 72 (estimated)

## Conditions studied

- Ebola Virus Disease
- COVID-19

## Interventions

- **BIOLOGICAL:** BioNTech - Pfizer COVID-19 vaccine
- **BIOLOGICAL:** 1mL saline solution
- **BIOLOGICAL:** rVSV∆G-ZEBOV-GP

## Key facts

- **NCT ID:** NCT06587503
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2024-12
- **Final completion:** 2025-05
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06587503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06587503, "Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06587503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*